Literature DB >> 2147116

Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease.

T Kuwert1, H W Lange, K J Langen, H Herzog, A Aulich, L E Feinendegen.   

Abstract

In 23 patients with moderate to severe Huntington's disease (HD) and 21 normal volunteers, the regional cerebral metabolic rate of glucose consumption (rCMRGlc) was measured in the cerebellum, thalamus, striatum, and cortex using positron emission tomography and the 18F-deoxyglucose method. In contrast to previous reports, rCMRGlc was reduced not only in the striatum, but also in the cerebral cortex of patients with HD as compared with normal subjects. No significant difference between HD patients and normal subjects was found for thalamic and cerebellar rCMRGlc. To investigate the relationship between the clinical status and rCMRGlc, correlation coefficients for the clinical data were calculated for absolute values of rCMRGlc and for cerebellar ratios (CR) of rCMRGlc. The duration of chorea correlated significantly only with the absolute values of frontoparietal and temporo-occipital rCMRGlc and with the CRs of most cortical regions evaluated. The severity of chorea correlated significantly only with lentiform nucleus rCMRGlc. The severity of dementia correlated significantly only with the frontoparietal and temporo-occipital rCMRGlc, the CRs of most cortical regions, and the CR for the caudate nucleus. The degree of disability correlated significantly with the CRs of all regions evaluated except the occipital and the superior frontal cortex. It appears from this study that there is a reduction not only for the striatum but also for cortical rCMRGlc in patients with manifest HD, and that the cortical reduction of rCMRGlc contributes to the severity of clinical symptoms in these patients. This challenges the concept that dementia in HD is of purely subcortical origin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147116     DOI: 10.1093/brain/113.5.1405

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  64 in total

1.  Huntington's disease and mitochondrial alterations: emphasis on experimental models.

Authors:  Verónica Pérez-De la Cruz; Paul Carrillo-Mora; Abel Santamaría
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

Review 2.  Imaging the role of GABA in movement disorders.

Authors:  Henning Boecker
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

Review 3.  The design of clinical trials for cell transplantation into the central nervous system.

Authors:  Pierre Cesaro
Journal:  NeuroRx       Date:  2004-10

Review 4.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

5.  Meclizine is neuroprotective in models of Huntington's disease.

Authors:  Vishal M Gohil; Nicolas Offner; James A Walker; Sunil A Sheth; Elisa Fossale; James F Gusella; Marcy E MacDonald; Christian Neri; Vamsi K Mootha
Journal:  Hum Mol Genet       Date:  2010-10-25       Impact factor: 6.150

Review 6.  Brain imaging and cognitive dysfunctions in Huntington's disease.

Authors:  Alonso Montoya; Bruce H Price; Matthew Menear; Martin Lepage
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

Review 7.  Positron emission tomography imaging of transplant function.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-10

Review 8.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

9.  Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease.

Authors:  N R Swerdlow; J Paulsen; D L Braff; N Butters; M A Geyer; M R Swenson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

10.  The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.

Authors:  D M Mann; R Oliver; J S Snowden
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.